Phase I human challenge study shows a single subcutaneous injection of the monoclonal antibody L9LS provides at least short-term protection against malaria.
List view / Grid view
NIAID Vaccine Research Center (VRC)
One dose of a monoclonal antibody developed at the US National Institutes of Health (NIH) prevented malaria for up to nine months.
A Phase I clinical trial to investigate mRNA-1273, a vaccine to prevent the spread of the coronavirus COVID-19, has begun in the US.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.